Are you attending the 2025 D.C. Summit by The Alliance for Longevity Initiatives (A4LI)? Join us on April 28-30th as our COO, Michael Ringel, JD, PhD, & CSO, Sharon Rosenzweig-Lipson, PhD, highlight legislative initiatives that promote a healthier human lifespan. Learn more: bit.ly/3Rzn4WN

Our COO, Michael Ringel, J.D., Ph.D., is presenting at the 2nd @Sheba_Medical Longevity Center Conference in Ramat Gan, Israel on May 7. We’re excited to discuss the economic aspects of longevity and to connect with industry peers. Reach out if you’d like to learn more!

This Healthy Vision Month, we’re spotlighting how vital eyesight is to the way we live & connect. Our Partial Epigenetic Reprogramming platform aims to restore visual function for those with optic neuropathies. Read more on the impact of vision loss: bit.ly/3YXj1HV

Did you know vision loss can raise the risk of depression, isolation, & cognitive decline? This Healthy Vision Month, we’re spotlighting the link between eye health and well-being and our mission to develop therapies to offset vision loss. For resources: bit.ly/3AqUGNZ

Our CEO, Jerry McLaughlin, COO, & Michael Ringel, J.D., Ph.D., look forward to joining fellow global leaders in Doha at the Qatar Economic Forum May 20 – 22 to work on practical solutions to the world’s most pressing problems. Learn more: bloom.bg/4dhQdPA QatarEconForum

Last week, members of the Life Bio team had a great time connecting with industry peers to discuss the latest in cell & gene therapy during ASGCT 2025, including our work to address age-related disease. Thank you ASGCT for a great conference!

This month, we're exploring how epigenetic reprogramming can target the root of aging to extend healthspan by restoring visual function. In @GENBio’s article, our CSO, Dr. Sharon Rosenzweig-Lipson, shares how our approach may reshape age-related disease: bit.ly/3EYpqM1

Are you attending the 2025 Aging Code Summit hosted by Longevity Global? Join us in Boston on June 11 from 1-1:30pm ET as our COO, Michael Ringel, JD, PhD, discusses the commercial path of age-related diseases and improving healthspan. Learn more: bit.ly/4ki2YwU

As Healthy Vision Month ends, we’re reflecting on the potential to preserve both vision and quality of life. Our mission, rooted in extending healthspan and protecting vision as we age, aims to reshape how we approach age-related diseases through cellular rejuvenation.

Our CSO, Sharon Rosenzweig-Lipson, Ph.D., is speaking at Founders Longevity Forum in partnership with Longevity Technology in London on June 10! Join us to explore progress in longevity and the future of extending healthspan. Reach out to connect! Register here: bit.ly/4lhvsYk

Attending Biotechnology Innovation Organization’s BIO International Convention? Don’t miss our CSO, Sharon Rosenzweig-Lipson, PhD, as she joins a panel discussion exploring the road from Nobel Prize-winning research to clinical studies. More information on the panel here: bit.ly/4kNNAYQ

Our COO, Michael Ringel, JD, PhD, will be a judge at the upcoming @GHEC2025 Event on June 25-26. Join us virtually or in person as global leaders highlight advancements in health tech innovation and the future landscape of healthcare. Register here: ghec2025.jp

Great connecting with @HMac8 at @BioSpace to highlight the growing momentum and interest of longevity. Our CSO, Sharon Rosenzweig-Lipson, PhD, discussed our focus on reversing and treating age-related diseases and enhancing longevity. Read more: bit.ly/467yOrF

In @GENBio’s article by Kathy Liszewski, our CSO, Sharon Rosenzweig-Lipson, PhD, highlights our Partial Epigenetic Reprogramming platform that aims to reset the epigenetic code and reverse age-related epigenetic changes. Read more: bit.ly/3HUIwnl

At the recent @GHEC2025, our COO, Michael Ringel, JD, PhD, presented on the potential impact of our partial epigenetic reprogramming platform and participated in a panel discussion exploring the future of healthcare innovation. Thank you all for an engaging discussion!

Our COO, Michael Ringel, JD, PhD, recently presented at Longevity Summit Dublin’s Global Longevity Conference to discuss preclinical results of our partial epigenetic reprogramming platform and its aim to extend longevity. Thank you to the organizers for an insightful event!

We are excited to announce a research collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to further expand our pipeline of cellular rejuvenation therapies. Read more:bit.ly/45hhaAU

Our CSO, Sharon Rosenzweig-Lipson, PhD, was featured in @BioSpace’s recent article, where she shares how our Partial Epigenetic Reprogramming Platform aims to target the biology of aging to offer therapies that extend healthspan. Read more: bit.ly/4o4rzaI

We received the #GreatPlaceToWork Certification for the second year in a row! This shows our commitment to maintaining a culture rooted in collaboration and a mission to prevent age-related diseases. Thank you to our team for continuing to build a space where innovation thrives!

#ICYMI, we announced a research collaboration with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS) to expand our cellular rejuvenation therapies. Read more in Longevity Technology’s article on how we aim to transform healthy aging: bit.ly/4763IkM